STUDY AT A GLANCE
What was studied.
15 Participants
Adults with persistent Long COVID symptoms.
14 Days
Open-label, non-randomized pilot study.
0.4 mL · 4–6× daily
Sublingual CelWel administration.
Fatigue + Symptom Tracking
Fatigue Severity Scale (FSS) and C19-YRS assessments.
Biomarker Review
Inflammatory cytokines and chemokines measured before and after.
Safety Monitoring
CBC, ESR, liver, and kidney markers reviewed throughout.
WHY IT MATTERS
Long COVID disrupts daily life in measurable ways.
Long COVID is often associated with lingering fatigue, brain fog, shortness of breath, mood changes, and reduced quality of life. This study focused heavily on fatigue because it remains one of the most common and disruptive post-COVID symptoms reported by patients.
KEY FINDINGS
What the study observed.
Fatigue scores improved
Mean fatigue scores decreased from 43.30 to 32.30 after 14 days — a statistically significant improvement.
C19-YRS symptoms improved
Improvements were reported across fatigue, cognition, anxiety, depression, mobility, personal care, usual activities, social role, and global health perception.
Biomarkers trended positively
PASC-related inflammatory score decreased in 11 of 15 participants over the study period.
Safety labs remained normal
All bloodwork and biochemical safety parameters stayed within normal range. No adverse events were reported.
SAFETY REVIEW
Safety was also evaluated.
The study reviewed bloodwork and biochemical safety markers before and after the 14-day period. According to the publication, all safety parameters remained within normal range, and no adverse events were reported during the study period.
WHAT THE STUDY SUGGESTS
A measured interpretation of the findings.
The findings suggest that CelWel has the potential to be effective and safe in adults with persistent post-COVID symptoms, with improvements observed in fatigue and broad symptom burden. The authors note that larger-scale trials are needed to establish the underlying mechanism.
IMPORTANT RESEARCH CONTEXT
Honest limitations make the data trustworthy.
This was a small, single-center pilot study with 15 participants. It was not randomized or placebo-controlled. The authors note that future research should compare CelWel with placebo or standard of care in a larger group over a longer period.
Individual results may vary. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Read the full published study.
Published in Diversity & Equality in Health and Care, April 2023.